← All drugs Report issue

moroctocog-alfa

Recombinant proteinexperimental

Clinical trial activity

9 trials · 2 clinical orgs · 0 marketing orgs

Phase 1

1

Phase 2

3

Phase 3

3

Phase 4

4

Earliest trial started Sep 1, 1994 (NCT00038909)

Timeline

2000s

Jan 1, 2005
Earliest Phase 3 Sponsor(trial)

2010s

Jan 1, 2012
Earliest Phase 1 Sponsor(trial)

Indications

Approved for

Hemophilia A

Studied for

Hemophilia A · Phase 4

Mechanism of action

Coagulation factor VIIIEXOGENOUS PROTEIN
Coagulation factor VIII exogenous protein
- Coagulation factor VIII (F8) ↗
Coagulation factor VIIISupplementation
F8 supplementation
- Coagulation factor VIII (F8) ↗

Chemistry & pharmacology

Chirality: Single Stereoisomer
Inorganic: No
Polymer: No
Multi-specific: No

Oral

No

Parenteral

No

Topical

No

Sources

ChEMBLCHEMBL2109137 ↗

Also known as

antihemophilic factor, human recombinant residues 743-1636 deleted
antihemphilic factor, recombinant human b-domain deleted
b-domain deleted recombinant factor viii
b-domain deleted recombinant factor viii
human factor viii, recombinant b-domain deleted
moroctocog alfa
moroctocog alfa
moroctocog alfa
moroctocog alfa
moroctocog alfa
recombinant factor viii sq
refacto
refacto
refacto af
r-viii sq

Clinical trials

NCT ID	Phase	Start date	Sponsor(s)
NCT04396639	Phase 4	Jan 25, 2020	Pfizer
NCT01579903	Phase 1	Aug 1, 2012	Pfizer
NCT00914459	Phase 4	Dec 1, 2009	Pfizer
NCT00759655	Phase 3	Jun 1, 2009	Pfizer
NCT00884390	Phase 4	May 1, 2009	Pfizer
NCT00765726	Phase 4	Feb 1, 2009	Pfizer
NCT00543439	Phase 3	Dec 11, 2007	Pfizer
NCT00141843	Phase 3	Jul 1, 2005	Pfizer, Wyeth
NCT00038909	N/A	Sep 1, 1994	Pfizer, Wyeth

Showing 9 of 9 trials

Page 1 / 1

Organizations

Research & Development (2)

Organization	Org type	Trials	As lead sponsor	Phases	Earliest year
Pfizer	For profit	9	9	4	1994
Wyeth	For profit	2	0	2	1994

2 organizations

Page 1 / 1